- Study Links High Antioxidant Intake To Changes in Offspring Development
- The Healthcare Burnout Backlash (pt 1): Burnout Reaches Well Beyond Clinicians
- The Healthcare Burnout Backlash (pt 1): Burnout Reaches Well Beyond Clinicians
- Even Mild Oxygen Loss in Preemies' First Hours Poses Lifelong Brain Risks: Study
- 12 oral surgery updates in 2026
- 5 ASC, MOB deals in California
- Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
- The Aspen Group’s 3-year growth recap: 40 moves
- Florida State University set to acquire Tallahassee hospital
- How Confusing Financial Journeys Undermine Revenue and Trust
- How Confusing Financial Journeys Undermine Revenue and Trust
- Misalignment, Not Malice: Rethinking Generational Conflict in Healthcare
- If AI ‘adds friction, it fails’: How Mayo Clinic scales technology
- As maternity units close, AdventHealth restores OB care in rural Kansas
- Oklahoma officials warn of new opioid
- The new metrics of healthcare technology ROI: What matters to healthcare leaders
- Hoag to launch transplant center in 2027
- MercyOne hospital to transition labor and delivery services
- MercyOne hospital to transition labor and delivery services
- Southeast metros lead US population growth as national gains slow
- 8 Medicare Advantage numbers to know in 2026
- 17 Senate Dems push back on 2027 ACA proposal
- Providence hospital closes inpatient pediatric unit
- Michigan finalizes Medicaid mental health assessment policy changes
- 10 financial notes on USPI’s growth over the past 3 years
- 15 new orthopedic practice, center openings in Q1
- The oral surgery technological revolution
- From Anxiety to Action: How Ambulatory Leaders Are Rebuilding Margins in 2026
- Where GI training may fall short
- What it took to become the world’s first ASC to offer Stryker’s robotic knee tech
- Medtronic’s win in spinal cord stimulator lawsuit upheld
- How the Trump Administration Uses Migrant Kids To Find and Detain Family Members
- Heartland Dental’s 3-year growth recap: 30+ moves
- Cencora’s $10B+ physician acquisition spree: A breakdown
- Tennessee physician practice acquired
- The FTC is coming for healthcare consolidation: 10 things physicians need to know
- Adventist Health sees momentum from insourcing revenue cycle operations
- Oral GLP-1s, COVID preventatives: 3 more drugs in the pipeline, Optum says payers should watch
- Unlicensed dentistry cases, DSO deals, legislation & more: 10 dentistry updates in Virginia
- Missouri system debuts mobile behavioral health unit
- Yale researchers study GLP-1’s potential for SUD
- Texas dental school receives $6.5M to expand pediatric dental, medical programs
- North Carolina autism provider to expand therapy access
- $3M Verdict Links Social Media to Anxiety and Depression
- West Virginia hospital to end OB delivery services
- 6 DSOs making headlines
- California hospital’s finances improve, cash position remains ‘dire’
- 1 in 5 metro markets face inpatient monopoly: 7 notes
- Minnesota system faces uncertainty amid Medicare delays
- Ohio county approves behavioral health crisis center plan
- The White House Delays CDC Pick
- New COVID 'Cicada' Variant Is Spreading — What Experts Want You To Know
- Op-ed: Empathy meets efficiency—how the responsible use of AI can transform Medicare
- Family Caregivers Provide $1 Trillion In Annual Labor, AARP Says
- ‘Health Doesn’t Need to Be Ludacris’: Bayer signs rapper-actor to multivitamin campaign
- Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA
- Healthy Lab Results May Mask Future Risks for Kids with Obesity
- At-Home Chemotherapy Is Safe, Feasible, Pilot Study Indicates
- What You Do While Sitting Could Predict Dementia Risk
- New Cholesterol Guidelines: What Patients and Caregivers Need to Know
- Want A Bootlicking Yes Man? Ask An AI Chatbot For Advice, Study Warns
- Specially Coated Implants Better For Breast Cancer Patients, Study Finds
- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Why private practice dentistry needs a better model
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Nonprofit highlights rural opioid care strategies
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- What the Health? From KFF Health News: A Headless CDC
- 20 behavioral health leaders challenge industry assumptions
- Recordati confirms it's weighing CVC Capital buyout offer of $12.6B
- 3 California behavioral health centers to close amid funding shifts
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- SCAN taps biopharma, CMS vet Aman Bhandari as its first chief AI officer
- Infosys to acquire Optimum Healthcare IT in $465M deal
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- Remarks at the Financial Stability Oversight Council Meeting
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- New therapy animal program aims to support 100K patients, providers
- Pulse check on Lilly's GLP-1 fortunes
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
The breath-taking extent to which health insurance interferes between patient and clinician comes to life in this Associated Press documentary.
Photo library clipped due to length, but remains available at the link.
Limits to anti-nausea pill coverage wear on cancer patients and doctors
Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits.
Doctors say restrictions on the number of tablets patients receive can hurt care. Pharmacy benefit managers say their limits guard against overuse, and they offer workarounds to get more tablets.
In between sit patients, who might ration pills or opt for less effective help for a dreaded side effect of radiation or chemotherapy.
The conflict shows how an array of coverages and poor communication can complicate even simple acts of care in the fragmented U.S. health care system.“This is sort of the dirty underbelly of the current health care environment,” said oncologist Dr. Fumiko Chino. “Insurance companies and pharmacy benefit managers are somehow weirdly ending up in my exam room, standing between me and my patients.”
Steven Manetta takes at least a half dozen pills daily to help keep a form of leukemia in remission. For more than a year, he rationed his go-to anti-nausea pill, ondansetron, known by the brand-name Zofran.
Manetta’s coverage through CVS Caremark paid for 18 ondansetron pills every 21 days. That forced him to sometimes use alternatives that make him extremely drowsy in order to stretch his supply. He only recently got approval for a 90-day supply.
“It’s just like an extra thing to think about all the time,” the 33-year-old Lemont, Illinois, resident said. “When you’re on so many medications, the ones with the least side effects are the ones you always want to reach for.”
Ondansetron hit the U.S. market more than 30 years ago. It was the first in a series of drugs that gave doctors a better way to control nausea and vomiting, said Dr. Alexi Wright, a Dana-Farber Cancer Institute oncologist who teaches at Harvard.
Wright and other cancer specialists call ondansetron a cornerstone treatment because of its relative safety, effectiveness and limited side effects.
The price doesn’t hurt either: Thirty tablets of ondansetron can cost under $12 through prescription discount websites.
Pharmacists and doctors say they’ve dealt with restrictions on anti-nausea drugs like ondansetron for years. Wright says she finds the limits “infuriating” in part because the drug is affordable.
More than half the plans sold on the U.S. individual insurance marketplace limit the number of ondansetron tablets that patients can get, according to preliminary results from a study by Chino and Michael Anne Kyle, a University of Pennsylvania researcher.
Pharmacist Yen Nguyen frequently sees these restrictions, including the limits from CVS Caremark that Manetta encountered.
“Over four or five months of chemotherapy, you’re fighting for dimes and nickels here,” said Nguyen, executive director of pharmacy for the Houston-area practice Oncology Consultants.
Jennette Murphy paid cash for ondansetron when her cancer treatment started earlier this year because she couldn’t get coverage for the amount her doctor requested. Then she got a letter telling her the drug wouldn’t be covered.
“It freaked me out,” the Tehachapi, California, resident said. “I’m like, ‘Really? Have you ever been through chemo?’”
Pharmacy benefit managers say they set limits based partly on the treatment and offer several ways for doctors to request more.
Prime Therapeutics limits 4- and 8-milligram prescriptions of ondansetron to 21 tablets over 30 days. That helps provide “maximum dosing” for seven days of treatment a month, chief clinical officer David Lassen said in an email.
He said quantity limits are approved by independent doctors and pharmacists. They help prevent waste and excessive use that may not be safe.
CVS Caremark spokesman Mike DeAngelis said his company bases limits on Food and Drug Administration guidelines. He added that the company can make a decision on requests for more tablets in less than 24 hours.
Doctors say they don’t always know when patients will need more.
Coverage limits vary, and some patients may not tell their doctor that they got a smaller-than-desired amount. Also, nausea intensity can be hard to gauge with newer treatments.
Chino says she wants patients to start with 90 tablets of ondansetron, enough to take the drug three times a day for a month if needed. But she often sees limits of 21 or 30 tablets.
“The fact that there’s still restrictive patterns on this very useful medication is insane,” said Chino, who recently moved from Memorial Sloan Kettering in New York to MD Anderson in Houston.
Limits can hurt patients who have big copayments for each refill or trouble getting to the drugstore, noted Dr. Ramy Sedhom, an oncologist and palliative care specialist with Penn Medicine Princeton Health.
“I have a lot of patients who only go to the pharmacy once a month when their niece or nephew is in town to pick up the (prescriptions),” he said.
If patients run out of ondansetron, even for a few days, uncontrolled vomiting can send them to emergency rooms or force a treatment pause, doctors say.
Murphy, the cancer patient, has avoided all of that. She said coverage started for ondansetron after her City of Hope cancer center doctor requested it.
She faces a stretch of chemotherapy cycles that will extend well into the fall. The treatments leave her bedridden for days with nausea even while taking ondansetron.
“I would hate to not have it,” she said.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.


















